Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on the VETIGEL(R) Hemostatic Product - The Future of Rapid Bleeding Control in Veterinary Medicine
Zomedica (OTCQB:ZOMDF) announced its upcoming Fourth Friday at Four webinar on August 22, 2025, focusing on their VETIGEL® hemostatic gel product. The webinar, scheduled for 4:00 PM ET, will showcase this plant-based solution designed for rapid bleeding control in veterinary medicine.
VETIGEL® offers veterinary professionals a quick and efficient method for managing soft tissue and superficial wounds through its syringe-based delivery system. The product accelerates clot formation and seals wounds, eliminating the need for traditional methods like manual pressure or cautery. The webinar will feature clinical case studies, real-world outcomes, and testimonials from veterinary professionals, followed by a live Q&A session with Zomedica's product and commercial leaders.
Zomedica (OTCQB:ZOMDF) ha annunciato il webinar "Fourth Friday at Four" in programma per il 22 agosto 2025, dedicato al suo prodotto VETIGEL® hemostatic gel. L'evento, previsto per le 16:00 ET, presenterà questa soluzione a base vegetale ideata per il rapido controllo delle emorragie in medicina veterinaria.
VETIGEL® offre ai professionisti veterinari un metodo rapido ed efficace per trattare ferite dei tessuti molli e superficiali tramite un sistema di somministrazione con siringa. Il prodotto accelera la formazione del coagulo e sigilla le ferite, eliminando la necessità di metodi tradizionali come la pressione manuale o la cauterizzazione. Il webinar includerà casi clinici, risultati reali e testimonianze di veterinari, seguiti da una sessione di domande e risposte dal vivo con i responsabili dei prodotti e commerciali di Zomedica.
Zomedica (OTCQB:ZOMDF) anunció su próximo webinar "Fourth Friday at Four" para el 22 de agosto de 2025, centrado en su producto VETIGEL® hemostatic gel. El seminario, programado para las 4:00 PM ET, mostrará esta solución de origen vegetal diseñada para el control rápido de hemorragias en medicina veterinaria.
VETIGEL® ofrece a los profesionales veterinarios un método rápido y eficaz para manejar heridas de tejidos blandos y superficiales mediante un sistema de administración con jeringa. El producto acelera la formación del coágulo y sella las heridas, eliminando la necesidad de métodos tradicionales como la presión manual o la cauterización. El webinar incluirá estudios clínicos, resultados prácticos y testimonios de profesionales veterinarios, seguidos de una sesión de preguntas y respuestas en vivo con los responsables de producto y comerciales de Zomedica.
Zomedica (OTCQB:ZOMDF)는 2025년 8월 22일에 개최되는 'Fourth Friday at Four' 웨비나를 발표했습니다. 이번 웨비나는 VETIGEL® hemostatic gel 제품에 초점을 맞추며, 동부 표준시(ET) 오후 4시에 진행됩니다. 이 식물성 기반 솔루션은 수의학에서 출혈을 빠르게 제어하도록 설계되었습니다.
VETIGEL®은 수의 전문가들에게 주사기 방식의 투여 시스템을 통해 연조직 및 표층 상처를 신속하고 효율적으로 관리할 수 있는 방법을 제공합니다. 이 제품은 혈병 형성을 촉진하고 상처를 봉합하여 수동 압박이나 소작과 같은 전통적인 방법을 대체합니다. 웨비나에서는 임상 사례, 실제 결과 및 수의사들의 사용 후기와 함께 Zomedica의 제품 및 상업 담당자들과의 실시간 질의응답이 진행됩니다.
Zomedica (OTCQB:ZOMDF) a annoncé son prochain webinaire "Fourth Friday at Four" qui se tiendra le 22 août 2025, axé sur son produit VETIGEL® hemostatic gel. Le webinaire, prévu à 16h00 ET, présentera cette solution d'origine végétale conçue pour un contrôle rapide des saignements en médecine vétérinaire.
VETIGEL® offre aux professionnels vétérinaires une méthode rapide et efficace pour gérer les plaies des tissus mous et superficielles grâce à un système d'administration par seringue. Le produit accélère la formation du caillot et scelle les plaies, supprimant le besoin de méthodes traditionnelles comme la pression manuelle ou la cautérisation. Le webinaire proposera des études de cas cliniques, des résultats concrets et des témoignages de vétérinaires, suivis d'une session de questions-réponses en direct avec les responsables produits et commerciaux de Zomedica.
Zomedica (OTCQB:ZOMDF) kündigte sein nächstes Webinar "Fourth Friday at Four" am 22. August 2025 an, das sich auf das Produkt VETIGEL® hemostatic gel konzentriert. Das Webinar, geplant für 16:00 Uhr ET, stellt diese pflanzenbasierte Lösung vor, die für die schnelle Blutstillung in der Veterinärmedizin entwickelt wurde.
VETIGEL® bietet Tierärzten eine schnelle und effektive Methode zur Behandlung von Weichteil- und Oberflächenverletzungen mittels eines injektionsspritzenbasierten Applikationssystems. Das Produkt beschleunigt die Gerinnungsbildung und verschließt Wunden, sodass traditionelle Methoden wie manueller Druck oder Kauterisation entfallen. Das Webinar umfasst klinische Fallstudien, Ergebnisse aus der Praxis und Erfahrungsberichte von Tiermedizinern, gefolgt von einer Live-Fragerunde mit den Produkt- und Vertriebsleitern von Zomedica.
- None.
- None.
Revolutionary Plant-Based Technology Gains Momentum as a Game-Changer in Wound Management
ANN ARBOR, MI / ACCESS Newswire / August 12, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering advanced diagnostic and therapeutic solutions for equine and companion animals, is pleased to announce the next installment of its Fourth Friday at Four webinar series, scheduled for Friday, August 22, 2025, at 4:00 PM ET.
This month's session will highlight VETIGEL® hemostatic gel, Zomedica's innovative, plant-based solution designed for rapid and effective control of bleeding. The VETIGEL product provides veterinary professionals a fast, easy-to-use option for managing bleeding in soft tissue and superficial wounds, making it ideal for both surgical and emergency applications. With a syringe-based delivery system, the VETIGEL product accelerates clot formation, quickly seals wounds, and eliminates the need for traditional methods like manual pressure or cautery.
What to Expect:
Overview of how VETIGEL hemostatic gel works in clinical settings
Real-world case studies and outcomes
Direct comments from veterinary professionals who are using and loving the product
Live Q&A session with Zomedica's product and commercial leaders
Whether you're a veterinary professional, industry partner, investor, or advocate for better animal care, this webinar will offer a behind-the-scenes look at a powerful new tool that's redefining wound management and improving patient outcomes.
Webinar Registration & Details
Connect, Learn, and Discover What's Next in Veterinary Innovation
Don't miss your chance to connect with industry experts, get a firsthand look at groundbreaking veterinary technologies, and explore what's next in animal healthcare. Whether you're a veterinary professional, industry partner, investor, or simply passionate about helping our pets live healthier lives-this series is for you.
Reserve your spot for the next session by clicking the link below:
https://bit.ly/fourthfridayinaugust
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on ACCESS Newswire
FAQ
When is Zomedica's (ZOMDF) Fourth Friday at Four webinar scheduled for August 2025?
What is VETIGEL and how does it work in veterinary medicine?
What topics will be covered in Zomedica's August 2025 VETIGEL webinar?
How can I register for Zomedica's VETIGEL webinar in August 2025?
